Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.49 |
| ▸ | CTSK | P43235 | 9/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245079 | 0.84 | CTSK (0.65) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL7424230 | 0.84 | CTSK (0.65) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL580779 | 0.84 | PPARA (0.53) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL14923491 | 0.84 | CTSS (0.49) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL10796108 | 0.84 | CTSS (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL4452913 | 0.84 | CTSS (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL10796111 | 0.84 | CTSS (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL588912 | 0.84 | PPARA (0.53) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL3686092 | 0.84 | CTSK (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL527131 | 0.84 | PPARA (0.53) | CTSSCTSKCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662856-B2 | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080249181-A1 | Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine | KOHN HAROLD | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249181-A1 | Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine | CD68, HAAO, HOGA1 | CTSS 1236/4885CTSK 781/4885CTSL 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.